Research programme: pyridazinone anti-psychotic therapeutics - Egis Pharmaceuticals/Servier

Drug Profile

Research programme: pyridazinone anti-psychotic therapeutics - Egis Pharmaceuticals/Servier

Alternative Names: EGIS-11148

Latest Information Update: 14 Sep 2010

Price : $50

At a glance

  • Originator Egis Pharmaceuticals
  • Developer Egis Pharmaceuticals; Servier
  • Class Ketones; Pyridazines
  • Mechanism of Action Alpha 1 adrenergic receptor modulators; Alpha 2 adrenergic receptor agonists; Alpha-2 adrenergic receptor modulators; Dopamine D2 receptor modulators; Serotonin 2A receptor modulators; Serotonin-6 receptor modulators; Serotonin-7 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Psychotic disorders; Schizophrenia

Most Recent Events

  • 03 Sep 2008 Pharmacodynamics data from a preclinical trial in Psychotic disorders presented at the 21st Annual Congress of the European College of Neuropsychopharmacology (ECNP-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top